Atorvastatin – a good choice. The efficacy and safety in the light of clinical trials Review article
Article Sidebar
Published:
Sep 30, 2015
Keywords:
atorvastatin, efficacy, safety
Main Article Content
Abstract
The benefits of statin therapy depend mainly on the reduction of LDL-C. Atorvastatin is known as a very strong statin – it reduces LDL-C by up 50–55%, without any significant increase in adverse events. The use of high doses of atorvastatin allows to achieve the prescribed therapeutic purposes, which reduces the risk of cardiovascular events. Numerous clinical trials confirmed the efficacy and safety of high doses of atorvastatin. Despite a lot of firm evidence from clinical trials and recommendations, doctors still prescribe intensive statin therapy too rarely.
Article Details
How to Cite
Wydra, W., & Kuch , M. (2015). Atorvastatin – a good choice. The efficacy and safety in the light of clinical trials. Medycyna Faktow (J EBM), 8(3(28), 28-32. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2293
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Reiner Z., Catapano A.L., De Backer G. et al.: ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32: 1769-1818.
2. Barylski M.: Atorwastatyna i rosuwastatyna w chorobach układu sercowo-naczyniowego – dlaczego, kiedy i u kogo je stosować? Geriatria 2012; 6: 166-182.
3. Charakterystyka Produktu Leczniczego.
4. Waters D.D., Guyton J.R., Herrington D.M. et al.: Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 2004; 93: 154-158.
5. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
6. Ray K.K., Cannon C.P., McCabe C.H. et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 2005; 46: 1405-1410.
7. Amarenco P., Bogousslavsky J., Callahan A. 3rd et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006; 355: 549-559.
8. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
9. Newman C., Tsai J., Szarek M. et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am. J. Cardiol. 2006; 97: 61-67.
10. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.
2. Barylski M.: Atorwastatyna i rosuwastatyna w chorobach układu sercowo-naczyniowego – dlaczego, kiedy i u kogo je stosować? Geriatria 2012; 6: 166-182.
3. Charakterystyka Produktu Leczniczego.
4. Waters D.D., Guyton J.R., Herrington D.M. et al.: Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 2004; 93: 154-158.
5. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
6. Ray K.K., Cannon C.P., McCabe C.H. et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol. 2005; 46: 1405-1410.
7. Amarenco P., Bogousslavsky J., Callahan A. 3rd et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 2006; 355: 549-559.
8. Nicholls S.J., Ballantyne C.M., Barter P.J. et al.: Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 2011; 365: 2078-2087.
9. Newman C., Tsai J., Szarek M. et al.: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am. J. Cardiol. 2006; 97: 61-67.
10. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.